Celtic aims to dramatically improve screening for colorectal cancer at an early stage, through a simple and non-invasive test, to ensure that in the future many fewer people will suffer from this type of cancer and many more will recover. The benefits of this test will be to improve early diagnosis, increase diagnostic coverage for patients not undergoing faecal immunochemistry (FIT) testing, and reduce the pressure on the health system due to excessive colonoscopy.